30-second summary
Forward opened its first San Francisco primary care clinic in 2017, raised $650M across Series A-E (The Founders Fund, Khosla, Marc Benioff, Serena Williams, Eric Schmidt, Marc Andreessen), expanding to 19 branded clinics in major US metros by 2022. The subscription model was $149/mo for unlimited primary care with proprietary diagnostic hardware. In 2023 Forward announced the CarePod — a self-service unattended glass-walled kiosk with blood-draw robot, body scanner, and AI-driven diagnosis — intended to scale the clinic footprint without requiring on-site clinicians. CarePods shipped Q1 2024 to underwhelming and widely-photographed malfunctions (locked-in patients, failed diagnostics). The company announced full shutdown November 12, 2024, refunded outstanding memberships, and wound down clinic operations over the following quarter.
The Pitch
"Primary care, re-engineered." 2016-2017 Wayback captures position Forward as a technology-first membership clinic — biometric scanners, integrated health dashboards, 24/7 mobile-app provider access. By 2022 the positioning emphasized "scale primary care to millions" by replacing some clinician labor with hardware and ML. The 2023 captures introduce the CarePod as the scaling mechanism — proprietary booths that would deliver primary-care services without scheduled appointments. The 2024 launch reviews (Business Insider, Statnews) documented specific failures: body-scan mis-segmentation, blood-draw calibration errors, patients locked inside malfunctioning pods for extended periods.
Five Causes of Death
Market
Membership-primary-care is a real category (One Medical was acquired by Amazon for $3.9B in 2023; Crossover Health serves enterprise segments). The model survives when (a) the buyer is an employer or payer rather than the individual, and (b) the unit economics are priced to cover provider labor and facility costs. Forward targeted individuals paying $149/mo and did not close meaningful payer contracts; the unit economics required 8-12 visits per member per year at full capacity, which the panel utilization did not support. The pivot to CarePod was an attempt to collapse the labor cost and expand geographically — targeting the right problem with the wrong technology.
Product
The original clinic product was well-reviewed by members. The hardware (body scanner, blood panel integration, in-clinic genetics) functioned. The issue was revenue per member — the $149/mo ceiling did not match the $40-80/mo profitable margin One Medical achieved with employer contracting. The CarePod pivot tried to solve the margin problem by removing on-site clinicians, but the specific technology (autonomous blood draw, in-pod diagnosis) was not yet reliable enough for consumer use in early 2024. Field failures compounded into brand damage. The product problem was "too ambitious too early" on the CarePod and "too individual-consumer-priced" on the clinic.
Team
Adrian Aoun is a strong founder (ex-Google special projects) with deep technology-platform experience. The Forward team brought in clinicians and health-system operators, but the organizational center of gravity remained tech-product rather than clinical-ops. The board (Khosla, Founders Fund, Benioff personal) was tech-heavy relative to healthcare-operator board seats. The decision to ship CarePods before reliability was proven — in a regulated category where device malfunction produces FDA attention and liability — reflects the tech-product decision DNA dominating clinical judgment at the executive level.
